Dr. Walkley has focused his career on the study of lysosomal diseases affecting brain, an interest that began with his early training in veterinary and comparative medicine and with the identification and development of these diseases in domesticated and laboratory animals. Educated at universities in his native state of Alabama, Dr. Walkley also carried out postgraduate studies at Auckland University in New Zealand, the University of Edinburgh in Scotland, and the Albert Einstein College of Medicine in New York. Dr. Walkley joined the faculty of the Albert Einstein College of Medicine in 1982 and today is professor in the Departments of Neuroscience, Pathology and Neurology and Director of the Sidney Weisner Laboratory of Genetic Neurological Disease. In 2010 he was named Director of the Rose F. Kennedy Intellectual and Developmental Disabilities Research Center at Einstein.
Dr. Walkley’s research combines skills in veterinary and comparative medicine and in neuropathology and cellular neuroscience in order to address key issues in the study of pathogenic cascades in lysosomal diseases affecting the brain. Dr. Walkley’s laboratory is also focused on developing treatment strategies for lysosomal diseases, including cell-mediated approaches as well as substrate reduction therapy. His lab spearheaded research on the use of bone marrow transplantation for the treatment of alpha-mannosidosis, as well as miglustat and hydroxypropyl beta-cyclodextrin for treatment of Niemann-Pick type C disease.
Dr. Walkley serves on the scientific advisory boards of several lysosomal disease groups - the National MPS Society, the International Society for Mannosidosis and Related Disorders (ISMRD), the ML4 Foundation and the National Tay-Sachs and Allied Diseases (NTSAD) foundation. He is also the Scientific Advisor for Dana’s Angel’s Research Trust (DART), the Hide and Seek Foundation for Lysosomal Disease Research, and A STAR for Ben Foundation.